Wegovy HD requires four weeks at the 2.4 mg dose first

On March 19, 2026, the FDA approved a new, higher-dose version of Wegovy called Wegovy HD, which contains 7.2 mg of semaglutide, triple the previous top dose of 2.4 mg ^[1][2]. The drug's label states that people can only move to the 7.2 mg dose after they have tolerated 2.4 mg for at least four weeks, and only if more weight loss is considered clinically needed ^[1].

The approval is based on the STEP UP trial, a 72-week study of 1,407 adults with obesity who did not have diabetes. Participants were randomly assigned in a 5:1:1 ratio to Wegovy HD, Wegovy 2.4 mg, or placebo, all alongside diet and exercise changes ^[1]. In the best-case scenario where everyone stayed on treatment, average weight loss was about 21% (20.7%) with Wegovy HD, about 18% (17.5%) with Wegovy 2.4 mg, and about 2% (2.4%) with placebo ^[1]. Counting everyone regardless of whether they stayed on the drug, the numbers were roughly 19% (18.8%) for Wegovy HD, 16% (15.5%) for Wegovy 2.4 mg, and 4% (3.9%) for placebo ^[1]. A separate summary of the same trial data put the last set of figures slightly differently, at 18.7%, 15.6%, and 3.9% ^[2]. About one in three people on Wegovy HD, 31.2%, lost 25% or more of their body weight, compared with 15.3% on the 2.4 mg dose and none on placebo ^[1]. Among people taking Wegovy HD, 89% lost at least 5% of their body weight, versus 38% on placebo ^[1].

The higher weight loss came with more side effects. Gastrointestinal problems were reported by 70.8% of people on the 7.2 mg dose, compared with 61.2% on the 2.4 mg dose ^[2]. Dysesthesia, an unusual and sometimes painful sensation such as burning or tingling under the skin, was also more common at the higher dose, affecting 22% to 22.9% of people on Wegovy HD compared with 6% to 6.0% on Wegovy 2.4 mg and 0.3% on placebo, depending on the source ^[1][2]. Common side effects listed for Wegovy HD include nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and flatulence ^[1].

Why it matters for patients

For people already on Wegovy 2.4 mg who want more weight loss, the new dose offers a path forward, but not an immediate one. The four-week tolerance requirement means the higher dose is a step after establishing that the lower dose is manageable, not a starting point ^[1]. The trial data suggest the trade-off is real: roughly 3 more percentage points of weight loss came with meaningfully higher rates of stomach upset and a specific skin sensation that was nearly four times more common at the higher dose ^[1][2]. One trial investigator, Dr. W. Timothy Garvey of the University of Alabama at Birmingham, said the results could "reshape healthcare professionals' expectations about what outcomes are possible" with Wegovy ^[1], but the data also show that not everyone who tolerates the lower dose will necessarily tolerate the higher one as easily.

Cost is also an open question. As of the approval, Novo Nordisk had not announced pricing for Wegovy HD ^[2].

What happens next

Novo Nordisk said Wegovy HD will become available in April 2026 through the same channels used for existing Wegovy products, including more than 70,000 U.S. pharmacies such as CVS and Costco, select telehealth providers, NovoCare Pharmacy, and GoodRx ^[1]. The company said details on insurance coverage and savings programs would also be released at that time ^[1]. Pricing has not yet been announced ^[2].